Desai RJ, Pawar A, Khosrow-Khavar F, et al. - This study was undertaken to investigate the risk of venous thromboembolism (VTE) with tofacitinib compared to tumor necrosis factor inhibitors (TNFIs) in patients with rheumatoid arthritis (RA). Researchers distinguished RA patients initiating tofacitinib or a TNFI without the use of any biologic or tofacitinib any time prior from IBM ‘MarketScan’ (2012-2018), Medicare (parts A, B, and D, 2012-2017), or ‘Optum‘Clinformatics (2012-2019) and followed until treatment discontinuation, treatment switch, insurance dis enrollment, or administrative censoring. They distinguished a sum of 42,201, 25,078, and 20,374 RA patients from MarketScan, Medicare, and Optum, respectively; of whom 7.1%, 7.1%, and 9.7% were tofacitinib initiators. It was shown that VTE occurred infrequently (< 1 per 100) in a total of 87,653 RA patients initiating tofacitinib or a TNFI. There was no evidence for an increased risk of VTE for tofacitinib vs TNFIs in RA patients.